Study Reveals Biomarkers That May Predict Vaccine Response Readiness

New research led by Arizona State University (ASU) indicates that biomarkers present in a person’s blood may reveal their readiness to respond to vaccines, including COVID-19. The study analyzed blood samples from over 4,000 participants, investigating antibodies that identified various antigens related to common viruses, bacteria, and autoimmune diseases.

Using artificial intelligence (AI), the researchers sought patterns in blood samples collected before and after COVID-19 vaccination. Their findings highlighted distinct antibody signatures that could differentiate between those likely to exhibit robust vaccine responses and those anticipated to have weaker reactions.

“What our study found is that certain biomarkers, when analyzed with AI, can predict who is likely to respond well to a vaccine, even before they receive it. This suggests that some people may be more immune-ready than others,” stated Joshua LaBaer, the study’s lead researcher and executive director of the Biodesign Institute at ASU.

The research, which appears in the journal Cell Press Blue, emphasizes that multiple factors influence vaccine responses, including age, sex, genetics, and health status. Interestingly, while individuals with compromised immune systems often produce weaker responses, vaccination outcomes can still vary widely even among those categorized similarly by health status.

In their analysis, the team measured immune responses to 185 antigens and examined 8,687 samples from 4,089 participants. This included both healthy individuals and those with immune suppression conditions like HIV and multiple myeloma. Several immunosuppressed groups were more likely to have reduced responses, yet simply classifying individuals based on their health did not consistently predict outcomes.

Certain antibodies that existed prior to vaccination, termed “sentinel” antibodies, surfaced as significant indicators of immune readiness. Increased levels of antibodies targeting common microbes, such as Staphylococcus aureus, RSV, and human respirovirus 3, were linked with stronger vaccine responses.

The comprehensive antibody profiling method enables a deeper understanding of immune states beyond looking at isolated antibodies. This approach benefits from machine learning’s ability to identify subtle biological relationships across vast datasets.

If these findings are substantiated in future research and applied to other vaccines, they could greatly enhance personalized vaccination strategies. This profiling could assist healthcare providers in identifying individuals who might benefit from additional vaccine doses or tailored follow-up strategies to bolster their immune response.